Company Overview

Dong-A Socio Holdings is acknowledged as a leading name in South Korea's Pharmaceutical industry with child companies as Dong-A ST, Dong-A Pharmaceutical and DM Bio. The business encompasses a broad range of activities related to the developing, manufacturing and distributing of ethical drugs, medical equipment, energy drinks, biopharmaceuticals and active pharmaceutical ingredients (API). Over the years, the company has built alliances with some of the biggest international companies to expand its market base. Its major products include Stillen tablet, Zydena tablet, and widely-available Bacchus energy drink, among others, with the latter having gained unprecedented popularity across the country.

Strategically moving ahead, the company went in for a structural rejig to find new growth engine after 80 years of its successful existence, splitting into three companies through stock split and asset carve-out - Dong-A Pharmaceutical, to solely focus on OTC business, Dong-A ST (Science & Technology) for the ethical drug business area, Dong-A Bio for Biopharmaceutical products in alliance with a Japanese Pharmaceuticals Mfg. Co. and the Dong-A Socio Holdings, the holding company, to focus on new investments such as biosimilar and other healthcare business, thus marking its foray into the biosimilar business.

Apart from having a strong base in the South Korean market, Dong-A Group has presence in approximately 40 countries in Europe, Latin America, and Asia where it markets its products, thus strengthening its foothold in the global pharmaceutical market. Dong-A also invests heavily in Zco l ᵐ ᵀ ÿ s đ

As the Dong-A Group wanted to use the new ERP system for cGMP-critical operations, it also wanted that the prospective software should have got the third-party testing and subsequent validation done. This was a pre-requisite for the company, as any such validation would have testified that the product is in-line with FDA and global regulatory guidelines and meets all the FDA and cGMP standards. Another requirement from the software was third-party manufacturing capability.

Quality Control

Then there were other needs too, as Dong-A needed both formula (in-process) Quality Control (QC), as well as final product QC capability from their new software. By having the in-process QC functionality, the company wanted to ensure consistency in quality during all stages of production, apart from the ability to conduct temperature check and check the manufacturing process on other parameters during production. There was an inherent need for the new ERP to have a robust QC module, with strong Non Conformance (NC) and Corrective Action Preventive Action (CAPA) system.

The Solution

Robust yet Flexible

Keeping all the aforementioned needs in mind, the Dong-A management wanted an experienced, competent, and specialized ERP solution rich with the features specific to the pharmaceutical industry. After reviewing demonstrations from quite a few companies, Dong-A narrowed the list to BatchMaster Manufacturing for SAP Business One, and offering from another prominent ERP player. In

The Results

BatchMaster Manufacturing for SAP Business One streamlined and automated Dong-A's critical business processes, proving as the ideal solution for all its three businesses by bringing them together. The fact that BatchMaster's offerings have third-party validation helped, as the company didn't have to think much before selecting it.

Meeting GMP Guidelines Made Easier

It is easier now for Dong-A to meet GMP guidelines by using backwards and forward traceability for the raw materials/Finished goods inward/outward transactions. GMP demand that each process should be documented properly to establish evidence that the produced drug meets its pre-determined specifications and quality attributes. It is thus important for the process manufacturers to create and maintain Batch Manufacturing Records (BMR), something Dong-A was missing with its legacy software & managing with hand-written BMR & MBR.

But with BatchMaster Manufacturing for SAP